How to buy Castle Biosciences stock | $50.25

Castle Biosciences, Inc is a diagnostics & research business based in the US. Castle Biosciences shares (CSTL) are listed on the NASDAQ and all prices are listed in US Dollars. Castle Biosciences employs 133 staff and has a trailing 12-month revenue of around USD$62.5 million.

How to buy shares in Castle Biosciences

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Castle Biosciences. Find the stock by name or ticker symbol: CSTL. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Castle Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$50.25, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Castle Biosciences, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Castle Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Castle Biosciences share price

Use our graph to track the performance of CSTL stocks over time.

Castle Biosciences shares at a glance

• Key figures

Information last updated 2020-10-19.

Latest market close	USD$50.25
52-week range	USD$15.26 - USD$55.31
50-day moving average	USD$50.4256
200-day moving average	USD$40.6264
Wall St. target price	USD$55
PE ratio	511.6302
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-3.14

Buy Castle Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Castle Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Castle Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Castle Biosciences price performance over time

Historical closes compared with the close of $50.25 from 2020-11-16

1 week (2020-11-25)	15.25%
1 month (2020-11-06)	-2.80%
3 months (2020-09-04)	4.58%
6 months (2020-06-05)	33.32%

1 year (2019-12-05)	70.74%
2 years (2018-12-02)	N/A
3 years (2017-12-02)	N/A
5 years (2015-12-02)	N/A

Is Castle Biosciences under- or over-valued?

Valuing Castle Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Castle Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Castle Biosciences's P/E ratio

Castle Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 512x. In other words, Castle Biosciences shares trade at around 512x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Castle Biosciences's EBITDA

Castle Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$5.9 million.

The EBITDA is a measure of a Castle Biosciences's overall financial performance and is widely used to measure a its profitability.

Castle Biosciences financials

Revenue TTM	USD$62.5 million
Operating margin TTM	8.88%
Gross profit TTM	USD$44.6 million
Return on assets TTM	2.95%
Return on equity TTM	9.22%
Profit margin	11.35%
Book value	$4.822
Market capitalisation	USD$983.5 million

TTM: trailing 12 months

Shorting Castle Biosciences shares

There are currently 733,752 Castle Biosciences shares held short by investors – that's known as Castle Biosciences's "short interest". This figure is 40.3% up from 522,859 last month.

There are a few different ways that this level of interest in shorting Castle Biosciences shares can be evaluated.

Castle Biosciences's "short interest ratio" (SIR)

Castle Biosciences's "short interest ratio" (SIR) is the quantity of Castle Biosciences shares currently shorted divided by the average quantity of Castle Biosciences shares traded daily (recently around 223024.92401216). Castle Biosciences's SIR currently stands at 3.29. In other words for every 100,000 Castle Biosciences shares traded daily on the market, roughly 3290 shares are currently held short.

However Castle Biosciences's short interest can also be evaluated against the total number of Castle Biosciences shares, or, against the total number of tradable Castle Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Castle Biosciences's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Castle Biosciences shares in existence, roughly 40 shares are currently held short) or 0.0642% of the tradable shares (for every 100,000 tradable Castle Biosciences shares, roughly 64 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Castle Biosciences.

Find out more about how you can short Castle Biosciences stock.

Castle Biosciences share dividends

We're not expecting Castle Biosciences to pay a dividend over the next 12 months.

Castle Biosciences overview

Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Frequently asked questions

• What percentage of Castle Biosciences is owned by insiders or institutions?

  Currently 27.997% of Castle Biosciences shares are held by insiders and 52.751% by institutions.

• How many people work for Castle Biosciences?

  Latest data suggests 133 work at Castle Biosciences.

• When does the fiscal year end for Castle Biosciences?

  Castle Biosciences's fiscal year ends in December.

• Where is Castle Biosciences based?

  Castle Biosciences's address is: 820 South Friendswood Drive, Friendswood, TX, United States, 77546

• What is Castle Biosciences's CUSIP number?

  Castle Biosciences's Committee on Uniform Securities Identification Procedures number is: 147905103